Clinical efficacy and safety of Tevagrastim^® (XM02), a biosimilar recombinant human granulocyte colony-stimulating factor

References

• Burgess AW, Metcalf D. The nature and action of granulocyte- macrophage colony stimulating factors. Blood. 1980;56(6):947–958.
   Web of Science ®Google Scholar
• Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science. 1985;229(4708):16–22.
   PubMed Web of Science ®Google Scholar
• Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319(6052):415–418.
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(4746):61–65.
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–170.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A(3):319–324.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [webpage on the Internet]. Teva- grastim. London, UK: European Medicines Agency; 2008 [updated March 7, 2011]. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000827/human_med_001089.jsp&mid=WC0b01ac058001d124. Accessed 25 June, 2012.
   Google Scholar
• US Food and Drug Administration [webpage on the Internet]. Drug approval reports by month. Silver Spring, MD: US Food and Drug Administration; Available from: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 25 June, 2012.
   Google Scholar
• Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. 2012;2:13–25.
   Google Scholar
• Bagalagel A, Mohammed A, MacDonald K, Abraham I. Clinical efficacy and safety of SB309, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. In press.
   Google Scholar
• Mohammed A, Bagalagel A, MacDonald K, Abraham I. Clinical efficacy and safety of XM01, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. In press.
   Google Scholar
• Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 2013;12(2):235–246.
   PubMed Web of Science ®Google Scholar
• del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009;4(6):736–740.
   Web of Science ®Google Scholar
• Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. LeukLymphoma. 2009;50(3):374–379.
   PubMed Web of Science ®Google Scholar
• Andreola G, Babic A, Rabascio C, Negri M, Martinelli G, Laszlo D. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation. Eur J Haematol. 2012;88(2):154–158.
   Web of Science ®Google Scholar
• Salesi N, Di Cocco B, Colonna M, Veltri E. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. Future Oncol. 2012;8(5):625–630.
   Web of Science ®Google Scholar